All In Biotech

Drug Trial Radar · NCT05674929

An Open-Label, Single Dose Study in Patients With Alcohol Use Disorder

An Open-Label, Phase 2a Single Dose Study in Patients With Alcohol Use Disorder

Last checked: Nov 19, 2026Latest source record: May 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

13

Actual

Start

May 30, 2023

Primary completion

Oct 2, 2024

Study completion Oct 2, 2024

Sponsor

Lead sponsor
Beckley Psytech LimitedIndustry
Sponsor type
Industry
First posted
Jan 9, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 64 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

An open-label, Phase 2a study to evaluate the safety, tolerability, and pharmacodynamic effects of a single intranasal dose of BPL-003 combined with relapse prevention psychological support, to explore the potential effects on alcohol use and related symptoms in patients with Alcohol Use Disorder.

Conditions

  • Alcohol Use Disorder

Interventions

  • BPL-003Drug

    A single dose administered intranasally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Treatment Emergent Adverse EventsTime frame: Up to 12 weeks
  2. Percentage of Participants With Clinically Significant Abnormal Laboratory TestsTime frame: Up to 12 weeks
  3. Percentage of Participants With Clinically Significant Abnormal Vital SignsTime frame: Up to 12 weeks
  4. Number of Participants With Post-baseline Suicidal Ideation or Behaviour Based on C-SSRS ScoreTime frame: Up to 12 weeks
  5. Time to Readiness for Discharge Post-dose Using the Readiness for Discharge Questionnaire (RDQ)Time frame: 1 Day
  6. Percentage of Participants With Occurrence of Reactivation Using the Reactivation Questionnaire (ReAQ)Time frame: Up to 12 weeks

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Clerkenwell Health

    London, United Kingdom

  • King's College London

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.